Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines

Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines

The ongoing coronavirus disease 2019 (COVID-19) pandemic is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Most of the currently approved SARS-CoV-2 vaccines use the prototype strain-derived spike (S) protein or its receptor-binding domain (RBD) as the vaccine antigen. The e...

Full description

Bibliographic Details
Main Authors: Yong Yang, Jinkai Zang, Shiqi Xu, Xueyang Zhang, Sule Yuan, Haikun Wang, Dimitri Lavillette, Chao Zhang, Zhong Huang
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Viruses
Subjects:
COVID-19
SARS-CoV-2 variants
receptor binding domain
S1
spike protein
vaccine
Online Access:https://www.mdpi.com/1999-4915/13/8/1421

Internet

https://www.mdpi.com/1999-4915/13/8/1421

Similar Items